Leukemia

3 currently open clinical trials
Treatment with ivosidenib or enasidenib for patients with mutations in enzymes (IDH1 or IDH2 mutation)
HOVON 150
Chemotherapy augmented by gilteritinib or midostaurin in patients with acute myeloid leukemia
HOVON 156
Addition of midostaurin in the treatment of “unfit” patients with AML or high-risk MDS
HOVON 155
All cancer types